← Leaderboards
Steven Miles
University Of California Los Angeles
$2,078,369
Attributed
$2,078,369
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,078,369 · 5
By mechanism
M01$2,078,369 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Ren Sun$20,189,518
- Ronald T Mitsuyasu$121,811,876
- Ohyun Kwon$8,027,122
- Xian-Jie Yang$9,325,084
- Daniel H Geschwind$113,418,228
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsDrug Screening /EvaluationHuman Therapy EvaluationHuman Immunodeficiency VirusDosageOpportunistic InfectionsAids TherapyAntineoplasticsClinical Trial Phase IDrug Adverse EffectDrug ToleranceKaposi'S SarcomaMicroorganism Disease ChemotherapyNeoplasm /Cancer ChemotherapyPharmacokineticsHelper T LymphocyteNeoplastic GrowthNeuroimmunomodulationCell MotilityPhenotypeRecombinant ProteinsDrug Administration Routes
Grant awards (13)
DOSE ESCALATING STUDY OF CUTANEOUS AIDS RELATED KAPOSI'S SARCOMA$207,266
M01 · FY2001 · RR
STEM CELL MOBILIZATION AND HARVESTING FROM THE PERIPHERAL BLOOD$207,266
M01 · FY2001 · RR
PHASE II TRIAL OF 9-CIS RETINOIC ACID (ALRT 1057) IN AIDS-KS (AMC PROT.002)$207,266
M01 · FY2001 · RR
PHASE I,DOOUBLE-BLINDED TRIAL OF RECOMBINANT HUMAN IL-12 IN HIV INFECTED PTS$207,266
M01 · FY2001 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE (3TC) VS. ZDV$207,266
M01 · FY2001 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE (3TC) VS. ZDV$207,266
M01 · FY2001 · RR
DOSE ESCALATING STUDY OF CUTANEOUS AIDS RELATED KAPOSI'S SARCOMA$207,266
M01 · FY2001 · RR
STEM CELL MOBILIZATION AND HARVESTING FROM THE PERIPHERAL BLOOD$207,266
M01 · FY2000 · RR
PHASE II TRIAL OF 9-CIS RETINOIC ACID (ALRT 1057) IN AIDS-KS (AMC PROT.002)$207,266
M01 · FY2000 · RR
PHASE I,DOOUBLE-BLINDED TRIAL OF RECOMBINANT HUMAN IL-12 IN HIV INFECTED PTS$207,266
M01 · FY2000 · RR
PHASE II TRIAL OF 9-CIS RETINOIC ACID (ALRT 1057) IN AIDS-KS (AMC PROT.002)$1,903
M01 · FY2000 · RR
PHASE I,DOOUBLE-BLINDED TRIAL OF RECOMBINANT HUMAN IL-12 IN HIV INFECTED PTS$1,903
M01 · FY2000 · RR
STEM CELL MOBILIZATION AND HARVESTING FROM THE PERIPHERAL BLOOD$1,903
M01 · FY2000 · RR